Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.32 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.30 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12282873 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2DPP4PLA2G2APLA2G5CA12 | |
| SCHEMBL14942955 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2DPP4PLA2G2APLA2G5CA12 | |
| SCHEMBL15144859 | 0.83 | PSMB5 (0.31) | — | |
| SCHEMBL24172623 | 0.83 | PSMB5 (0.31) | — | |
| SCHEMBL14942951 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL17020280 | 0.81 | PLA2G2A (0.37) | SMN1; SMN2DPP4PLA2G2APLA2G5FFAR3 | |
| SCHEMBL18881153 | 0.81 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL18067362 | 0.79 | MME (0.33) | SMN1; SMN2PLA2G2APLA2G5ALDH1A1 | |
| SCHEMBL24421010 | 0.78 | TDP1 (0.32) | SMN1; SMN2PLA2G2APLA2G5CA12CA14 | |
| SCHEMBL12648972 | 0.78 | SMN1; SMN2 (0.32) | SMN1; SMN2PLA2G2APLA2G5CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2986626-B1 | COMPOUNDS USEFUL IN THE TREATMENT AND/OR CARE OF THE SKIN AND THEIR COSMETIC OR PHARMACEUTICAL COMPOSITIONS | LUBRIZOL ADVANCED MAT INC (US) | 2017-06-07 | — | — | EP | disclosed |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-11-10 | — | — | US | disclosed |
| US-20160206680-A1 | ANTI-TRYPANOSOME COMPOUNDS AND TREATMENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-07-21 | — | — | US | disclosed |
| US-9388232-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-07-12 | — | — | US | disclosed |
| US-8993597-B2 | Apolipoprotein A-I mimics | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-03-31 | — | — | US | disclosed |
| US-20140309426-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | INSTITUT DE CARDIOLOGIE DE MONTRÉAL (CA) | 2014-10-16 | — | — | US | disclosed |
| US-20140221276-A1 | FURTHER NOVEL ANTI-PARASITIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-09-05 | — | — | US | disclosed |
| WO-2012021704-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2011127350-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011091417-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011081918-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC (US) | 2011-07-07 | — | — | WO | disclosed |
| WO-2011031934-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
| WO-2010148006-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010099527-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309426-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF LEFT VENTRICULAR DIASTOLIC DYSFUNCTION COMPRISING AN APOLIPOPROTEIN PEPTIDE/PHOSPHOLIPID COMPLEX | APOB, FABP3, PLTP | SMN1; SMN2 2192/4885DPP4 452/4885PLA2G2A 66/4885 |
| US-20160324923-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | SMN1; SMN2 2795/4885DPP4 73/4885PLA2G2A 528/4885 |
| US-20130231459-A1 | APOLIPOPROTEIN A-I MIMICS | APOB, APOL1, LIPG | SMN1; SMN2 2795/4885DPP4 73/4885PLA2G2A 528/4885 |
| US-20160206680-A1 | ANTI-TRYPANOSOME COMPOUNDS AND TREATMENTS | PDF, TUFM, TRAP1 | SMN1; SMN2 2149/4885DPP4 2386/4885PLA2G2A 659/4885 |
| US-20140221276-A1 | FURTHER NOVEL ANTI-PARASITIC COMPOUNDS | PTMS, LRBA, PDF | SMN1; SMN2 3959/4885DPP4 998/4885PLA2G2A 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.